International Journal of Cardiology
Volume 125, Issue 2 , Pages 149-153 , 10 April 2008

Beta-blocker therapy in heart failure in the elderly

References 

  1. Komajda M, Follath F, Swedberg K, et al. The EuroHeart Failure Survey programme — a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J. 2003;24:464–474
  2. ADHERE Registry. http://www.adhereregistry.com/. 8-9-2006.
  3. Cleland JG, Cohen-Solal A, Aguilar JC, et al. IMPROVEMENT of Heart Failure Programme Committees and Investigators. Improvement programme in evaluation and management; Study Group on Diagnosis of the Working Group on Heart Failure of The European Society of Cardiology. Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet. 2002;360:1631–1639
  4. Tsutsui H, Tsuchihashi-Makaya M, Kinugawa S, Goto D, Takeshita A. Characteristics and outcomes of patients with heart failure in general practices and hospitals. Circ J. 2007;71(4):449–454
  5. CIBIS-II . The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9–13
  6. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651–1658
  7. MERIT-HF . Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001–2007
  8. Flather M, Shibata M, Coats A, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215–225
  9. Deedwania PC, Gottlieb S, Ghali JK, Waagstein F, Wikstrand JC. Efficacy, safety and tolerability of beta-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure. Eur Heart J. 2004;25:1300–1309
  10. Dobre D, van Veldhuisen DJ, DeJongste MJ, et al. Prescription of beta-blockers in patients with advanced heart failure and preserved left ventricular ejection fraction. Clinical implications and survival. Eur J Heart Fail. 2007;9(3):280–286
  11. Franciosa JA, Nelson JJ, Lukas MA, et al. COHERE Participant Physicians. Heart failure in community practice: relationship to age and sex in a beta-blocker registry. Congest Heart Fail. 2006;12(6):317–323
  12. Macdonald PS, Hill J, Krum H COLA II Investigators. The impact of baseline HR and BP on the tolerability of carvedilol in the elderly: the COLA (Carvedilol Open Label Assessment) II Study. Am J Cardiovasc Drugs. 2006;6(6):401–405
  13. Fowler Michael B, Lottes Sandra R, Nelson Jeanenne J, et al. β-Blocker dosing in community-based treatment of heart failure. Am Heart J. 2007;153(6):1029–1036
  14. Macdonald PS, Keogh AM, Aboyoun CL, Lund M, Amor R, McCaffrey DJ. Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure. J Am Coll Cardiol. 1999;33:924–931
  15. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 1996;94:2807–2816
  16. Lenzen MJ, Boersma E, Reimer WJ, et al. Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure. Eur Heart J. 2005;26:2706–2713
  17. Simon T, Mary-Krause M, Funck-Brentano C, Lechat P, Jaillon P. Bisoprolol dose–response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study (CIBIS II). Eur Heart J. 2003;24:552–559
  18. Wikstrand J, Hjalmarson A, Waagstein F, et al. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure — analysis of the experience in Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF). J Am Coll Cardiol. 2002;40:491–498
  19. Sin DD, McAlister FA. The effects of beta-blockers on morbidity and mortality in a population-based cohort of 11,942 elderly patients with heart failure. Am J Med. 2002;113:650–656
  20. Dobre D, DeJongste MJ, Lucas C, et al. Effectiveness of beta blocker therapy in daily practice patients with advanced chronic heart failure; is there an effect-modification by age?. Br J Clin Pharmacol. 2007;63:356–364
  21. Jourdain P, Jondeau G, Funck F, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: The STARS-BNP Multicenter Study. J Am Coll Cardiol. 2007;49(16):1733–1739
  22. Le Jemtel TH, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol. 2007;49(2):171–180

PII: S0167-5273(07)01625-7

doi: 10.1016/j.ijcard.2007.10.010

International Journal of Cardiology
Volume 125, Issue 2 , Pages 149-153 , 10 April 2008

Article Tools